This Crypto Is Set to Explode in December

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Andrew John Hugh Sims net worth and biography

Andrew Sims Biography and Net Worth

CFO of Plus Therapeutics

Andrew J. Sims is the VP of Fin. & CFO at Plus Therapeutics.

What is Andrew John Hugh Sims' net worth?: The estimated net worth of Andrew John Hugh Sims is at least $10,698.35 as of September 10th, 2024. Dr. Sims owns 9,815 shares of Plus Therapeutics stock worth more than $10,698 as of December 22nd. This net worth evaluation does not reflect any other assets that Dr. Sims may own. Additionally, Dr. Sims receives an annual salary of $498,510.00 as CFO at Plus Therapeutics. Learn More about Andrew John Hugh Sims' net worth.
How old is Andrew John Hugh Sims?: Dr. Sims is currently 51 years old. There are 4 older executives and no younger executives at Plus Therapeutics. The oldest executive at Plus Therapeutics is Dr. Norman D. LaFrance FACNP, FACP, M.D., Chief Medical Officer & Senior VP, who is 76 years old. Learn More on Andrew John Hugh Sims' age.
What is Andrew John Hugh Sims' salary?: As the CFO of Plus Therapeutics, Inc., Dr. Sims earns $498,510.00 per year. There are 2 executives that earn more than Dr. Sims. The highest earning executive at Plus Therapeutics is Dr. Marc H. Hedrick M.B.A., M.D., President, CEO & Director, who commands a salary of $945,340.00 per year. Learn More on Andrew John Hugh Sims' salary.
How do I contact Andrew John Hugh Sims?: The corporate mailing address for Dr. Sims and other Plus Therapeutics executives is 4200 MARATHON BLVD SUITE 200, AUSTIN TX, 78756. Plus Therapeutics can also be reached via phone at 737-255-7194 and via email at [email protected]. Learn More on Andrew John Hugh Sims' contact information.
Has Andrew John Hugh Sims been buying or selling shares of Plus Therapeutics?: Andrew John Hugh Sims has not been actively trading shares of Plus Therapeutics in the last ninety days. Most recently, on Tuesday, September 10th, Andrew John Hugh Macintyr Sims bought 4,098 shares of Plus Therapeutics stock. The stock was acquired at an average cost of $1.27 per share, with a total value of $5,204.46. Following the completion of the transaction, the chief financial officer now directly owns 9,815 shares of the company's stock, valued at $12,465.05. Learn More on Andrew John Hugh Sims' trading history.
Who are Plus Therapeutics' active insiders?: Plus Therapeutics' insider roster includes Marc Hedrick (CEO), Robert Lenk (Director), Greg Petersen (Director), and Andrew Sims (CFO). Learn More on Plus Therapeutics' active insiders.
Are insiders buying or selling shares of Plus Therapeutics?: In the last year, Plus Therapeutics insiders bought shares 7 times. They purchased a total of 48,059 shares worth more than $82,744.90. The most recent insider tranaction occured on September, 13th when Director Richard J Hawkins bought 4,000 shares worth more than $6,000.00. Insiders at Plus Therapeutics own 5.5% of the company. Learn More about insider trades at Plus Therapeutics.
Information on this page was last updated on 9/13/2024.

Andrew John Hugh Sims Insider Trading History at Plus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/10/2024	Buy	4,098	$1.27	$5,204.46	9,815
5/8/2024	Buy	4,902	$2.04	$10,000.08	5,717
4/26/2022	Buy	200	$10.05	$2,010.00	815
3/1/2022	Buy	133	$16.50	$2,194.50
11/2/2021	Buy	66	$27.90	$1,841.40
10/26/2021	Buy	133	$25.05	$3,331.65
7/27/2021	Buy	132	$30.75	$4,059.00	132

Andrew John Hugh Sims Buying and Selling Activity at Plus Therapeutics

Plus Therapeutics Company Overview

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Today's Range

Now: $1.09

$0.97

$1.11

50 Day Range

MA: $1.29

$0.99

$1.45

2 Week Range

Now: $1.09

$0.93

$2.67

Volume

48,987 shs

Average Volume

64,415 shs

Market Capitalization

$6.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

This Crypto Is Set to Explode in December

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

Andrew Sims Biography and Net Worth

What is Andrew John Hugh Sims' net worth?

How old is Andrew John Hugh Sims?

What is Andrew John Hugh Sims' salary?

How do I contact Andrew John Hugh Sims?

Has Andrew John Hugh Sims been buying or selling shares of Plus Therapeutics?

Who are Plus Therapeutics' active insiders?

Are insiders buying or selling shares of Plus Therapeutics?